THE ASSESSMENT OF LORAZEPAM EFFECTIVENESS TO REDUCE ACUTE AND DELAYED NAUSEA AND VOMITING AMONG CHEMOTHERAPY PATIENTS: A RANDOMIZED CLINICAL TRIAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MOLANA S.H.; AFZALI M.; EMAMI J.; TAJVIDI M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Ebnesina Year:2011 | Volume:14 | Issue:1-2 (39-40) Page(s): 4-9

Download Full-Text

Persian Verion

View:

1,892

Download:

Cites:

Information Journal Paper

Title

THE ASSESSMENT OF LORAZEPAM EFFECTIVENESS TO REDUCE ACUTE AND DELAYED NAUSEA AND VOMITING AMONG CHEMOTHERAPY PATIENTS: A RANDOMIZED CLINICAL TRIAL

Author(s)

MOLANA S.H. | AFZALI M. | EMAMI J. | TAJVIDI M. | Issue Writer Certificate

Keywords

LORAZEPAMQ4

METOCLOPRAMIDEQ4

VOMITING-NAUSEA CHEMOTHERAPY PATIENTSQ4

Abstract

Background: Cancer is defined as one of the most leading causes of death in Iran, as well as the whole world. Chemotherapy as a common modality might have several consequences such as nausea and vomiting.Metoclopramide, anti 5HI3, antagonist and benzodiazepines are used to decrease vomiting symptoms. However, the effectiveness of benzodiazepine is unknown so far. This study aimed to evaluate the role of LORAZEPAM in decreasing of METOCLOPRAMIDE dosage.Materials and methods: Seventy consecutive patients were sampled to assess the outcome. LORAZEPAM was randomly added to premedication drugs in one of two chemotherapy courses for all patients. The LORAZEPAM proscribed one night before chemotherapy and continued for three days after chemotherapy every 12 hours.Results: The frequency and severity of nausea showed a significant decrease with LORAZEPAM vs. grade II+ acute decrease from 85% to 53% (p<0.0001), grade II+ delayed nausea decreas from 86.24% to 55%. (p<0.0001), grade II+ delayed vomiting decrease from 69.14% to 13% (p<0.0001).Conclusion: Despite previous studies the results of this study show a clear impact of LORAZEPAM benefits on the decrease severity & frequency of nausea and vomiting.

Cites

No record.

References

No record.

Cite

APA: Copy

MOLANA, S.H., AFZALI, M., EMAMI, J., & TAJVIDI, M.. (2011). THE ASSESSMENT OF LORAZEPAM EFFECTIVENESS TO REDUCE ACUTE AND DELAYED NAUSEA AND VOMITING AMONG CHEMOTHERAPY PATIENTS: A RANDOMIZED CLINICAL TRIAL. EBNESINA, 14(1-2 (39-40)), 4-9. SID. https://sid.ir/paper/228627/en

Vancouver: Copy

MOLANA S.H., AFZALI M., EMAMI J., TAJVIDI M.. THE ASSESSMENT OF LORAZEPAM EFFECTIVENESS TO REDUCE ACUTE AND DELAYED NAUSEA AND VOMITING AMONG CHEMOTHERAPY PATIENTS: A RANDOMIZED CLINICAL TRIAL. EBNESINA[Internet]. 2011;14(1-2 (39-40)):4-9. Available from: https://sid.ir/paper/228627/en

IEEE: Copy

S.H. MOLANA, M. AFZALI, J. EMAMI, and M. TAJVIDI, “THE ASSESSMENT OF LORAZEPAM EFFECTIVENESS TO REDUCE ACUTE AND DELAYED NAUSEA AND VOMITING AMONG CHEMOTHERAPY PATIENTS: A RANDOMIZED CLINICAL TRIAL,” EBNESINA, vol. 14, no. 1-2 (39-40), pp. 4–9, 2011, [Online]. Available: https://sid.ir/paper/228627/en

Related Journal Papers